---
title: "BIOMERICA INC 1Q FY2027: Revenue $1.27M, EPS $(0.37) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302024940.md"
description: "BIOMERICA INC reported Q1 FY2027 results with revenue of $1.265M, down 8.3% YoY due to lower clinical lab orders, and a net loss of $(1.232M). Diluted EPS was $(0.37). Business highlights include increased OTC sales, Medicare rollout for inFoods®, FDA clearance for hp+detect™, a $1.75M CDM services agreement, and a $2.23M private placement."
datetime: "2026-10-15T21:11:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302024940.md)
  - [en](https://longbridge.com/en/news/302024940.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302024940.md)
generator: "portal-rs"
---

# BIOMERICA INC 1Q FY2027: Revenue $1.27M, EPS $(0.37) — 10-Q Summary

BIOMERICA INC reported first-quarter fiscal 2027 results, with revenue of $1.265M, a net loss of $(1.232M) attributable to shareholders and diluted EPS of $(0.37), compared with revenue of $1.38M and a small net income in the year‑ago quarter — 10-Q Summary.

**Financial Highlights**

-   Revenue was $1.265M for Q1 FY2027 (three months ended Aug 31, 2026), compared with $1.380M in the prior-year quarter; YoY change (8.3%).
-   Net income was a loss of $(1.232M) attributable to shareholders for Q1 FY2027, versus $2.0K net income in the year‑ago quarter.
-   Diluted EPS was $(0.37) for Q1 FY2027, compared with $0.00 in the year‑ago quarter.

**Business Highlights**

-   Revenue mix shifted as lower clinical lab orders drove the 8% YoY decline, while OTC sales increased and contract manufacturing remained steady.
-   Commercial rollout of inFoods® IBS advanced with Medicare payment rate established and initial Medicare orders showing month‑over‑month growth.
-   hp+detect™ secured FDA 510(k) clearance and UK MHRA registration, with initial commercial orders and reorders in Europe.
-   Signed a target master services agreement exceeding $1.75M for CDM services to leverage existing FDA/ISO‑certified manufacturing capacity.
-   Completed a $2.23M private placement to support commercialization, reimbursements, and to scale sales and marketing efforts.

Original SEC Filing: BIOMERICA INC \[ BMRA \] - 10-Q - Oct. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BMRA.US](https://longbridge.com/en/quote/BMRA.US.md)

## Related News & Research

- [Biomerica publishes revised annual report filing (Form 10-K/A)](https://longbridge.com/en/news/300348726.md)
- [Biomerica CEO Zackary S. Irani reports acquisition of $50,000 common shares](https://longbridge.com/en/news/297235006.md)
- [Alphabet Inc. $GOOG Stock Sold by Axxcess Wealth Management LLC](https://longbridge.com/en/news/302979783.md)
- [HCA Healthcare, Inc. $HCA Stock Holdings Lowered by Robeco Institutional Asset Management B.V.](https://longbridge.com/en/news/302982678.md)
- [Is Elevance Health (ELV) Still Undervalued Following Strong Earnings And Higher 2026 Guidance?](https://longbridge.com/en/news/302983253.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**